NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural ...
For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...
The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...
When a biopharma company known for its expertise in a specific domain turns to a collaborator to expand its capabilities in ...
Gossamer Bio is picking up the pieces after failing to bring its only late-stage drug to market. The local biotech plans to lay off 65 San Diegans, almost half of its total workforce. While the ...
In February, a small biotech company reached a breakthrough with the FDA, agreeing to a clinical trial plan. The problem: The ...
The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...
Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...
CHENGDU, China, April 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', 6990.HK) announced that results from both the ovarian cancer cohort ...
StockStory.org on MSN
Reflecting on drug development inputs & services stocks’ Q4 earnings: IQVIA (NYSE:IQV)
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', 6990.HK) today announced that following an application to The Stock Exchange of Hong Kong Limited (the 'Stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results